secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0000914475-25-000034
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine reports Q4 INGREZZA sales $615M (+23% YoY); 2025 guidance $2.5-2.6B
------------------------------------------------------------------------------

- INGREZZA net product sales $2.3B for FY2024, up 26% YoY; Q4 sales $615M (+23% YoY).
- CRENESSITY (crinecerfont) approved Dec 2024 for classic CAH; initial Q4 sales $2M.
- Non-GAAP diluted EPS Q4 $1.69 vs $1.54 prior year; GAAP EPS $1.00 vs $1.44 (higher stock-based comp).
- 2025 INGREZZA sales guidance $2.5-2.6B; Phase 3 osavampator and NBI-568 starting H1 2025.
- Completed $300M ASR program in Feb 2025, repurchased ~2.3M shares; cash $1.816B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000034/0000914475-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000034/nbix-20250206.htm
  HTML page:      https://secwatch.observer/filing/0000914475-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer